Raphael Eric Steiner, M.D.

Peer-Reviewed Articles

1. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv 3(9):1356-1367, 2019. PMID: 31036721.
2. Steiner R, Kridel R, Giostra E, McKee T, Achermann R, Mueller N, Manuel O, Dickenmann M, Schuurmans MM, de Leval L, Fehr T, Tinguely M, Binet I, Cogliatti S, Haralamvieva E, Koller M, The Swiss Transplant Cohort Study Stcs , Dietrich PY. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland. Swiss Med Wkly 148:w14596, 2018. e-Pub 2018. PMID: 29518251.
3. Steiner RE, Romaguera J, Wang M. Current trials for frontline therapy of mantle cell lymphoma. J Hematol Oncol 11(1):13, 2018. e-Pub 2018. PMID: 29374487.
4. Steiner RE, Orlowski RZ, Lee HC. Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient. Acta Haematol 139(1):67-70, 2018. e-Pub 2018. PMID: 29402766.
5. Steiner RE, Manasanch EE. Carfilzomib boosted combination therapy for relapsed multiple myeloma. Onco Targets Ther 10:895-907, 2017. e-Pub 2017. PMID: 28243125.
6. Steiner R, Beyer J. [Post treatment follow-up of patients with testicular cancer by primary care physicians]. Praxis (Bern 1994) 103(3):125-32; quiz 131, 2014. PMID: 24468451.
7. Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EE. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma:1-7. e-Pub 2018. PMID: 30227761.

Abstracts

1. P. Strati, P. Alcedo Andreade, D. Sano, V. Rao, P. Singh, R. Miranda, J. Gunther, C. Pinnix, B. Dabaja, H.J. Lee, R. Steiner. RELAPSED AND REFRACTORY NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL): A US ANALYSIS FROM MD ANDERSON CANCER CENTER. Hematological ONCOLOGY ICML Abstract(Abstract No: 471), 2019.
2. B. Dabaja, M. Gule-Monroe, J.R. Gunther, S. Milgrom, T. Sheu, R. Nair, S. Ahmed, R. Steiner, P. Strati, L. Nastoupil, S. Neelapu, C. Pinnix, N. Fowler. DIFFUSE LARGE B CELL LYMPHOMA WITH SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT: CAN MRI PATTERN HELP PREDICTING OUTCOME?. Hematological ONCOLOGY ICML Abstract(Abstract No: 406), 2019.
3. Jason Westin, Loretta J. Nastoupil, Luis Fayad, Fredrick B. Hagemeister, Yasuhiro Oki, Francesco Turturro, Sairah Ahmed, Maria Alma Rodriguez, Hun Ju Lee, Raphael Steiner, Ranjit Nair, Simrit Parmar, Ken H Young, Timothy McDonnell, Hubert Chuang, Michael Richard Green, Sattva Swarup Neelapu, Richard Eric Davis. Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. ASCO Abstract, 2019.
4. Preetesh Jain, MBBS,MDDM,PhD , Shuangtao Zhao, PhD , Rashmi Kanagal-Shamanna, MD , Lucy Navsaria, MB BCh BAO , Holly Hill , Ankita Misra , Krystle Nomie, PhD , Changying Jiang, PhD , Yixin Yao, PhD , Liang Zhang, MD PhD , Loretta J. Nastoupil, MD MSc , F. B. Hagemeister, MD , Jason R. Westin, MD , Ranjit Nair, MD , Raphael Eric Steiner, MD , Onyeka Oriabure , Wendy Chen , Guilin Tang, MD , C. Cameron Yin, MD PhD , Keyur Patel, MD PhD , Jorge Enrique Romaguera, MD , Nathan H. Fowler, MD , Linghua Wang, PhD , Michael L. Wang, MD. Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL. Blood(Blood (2019) 134 (Supplement_1): 2815), 2019.
5. Paolo Strati, MD , Sudhakar Tummala , Loretta J. Nastoupil, MD MSc , Jason R. Westin, MD , Luis Fayad, MD , Sairah Ahmed, MD , Nathan H. Fowler, MD , F. B. Hagemeister, MD , Hun Ju Lee, MD , Swaminathan P. Iyer, MD , Ranjit Nair, MD , Simrit Parmar, MBBS , Maria Alma Rodriguez, MD , Felipe Samaniego, MD , Raphael Eric Steiner, MD , Michael L. Wang, MD , Chelsea Camille Pinnix, MD PhD , Sherry Adkins, ANP , Catherine M. Claussen, MS , Charles Martinez , Misha Hawkins , Nicole Johnson , Shirley George , Sattva S Neelapu, MD , Linda Chi, MD. Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Blood(Blood (2019) 134 (Supplement_1): 765), 2019. e-Pub 2019.
6. J.R. Westin, L. Nastoupil, L. Fayad, F. Hagemeister, K. Young, T. McDonnell, S. Neelapu, R.E. Davis, M. Green, S. Ahmed, R. Nair, R. Steiner, H. Lee, M. Rodriguez, S. Parmar, H. Chuang. VERY EARLY FDG PET/CT SCAN MAY PREDICT OUTCOMES IN RELAPSED OR REFRACTORY DLBCL PATIENTS TREATED WITH SALVAGE THERAPY. Hematological ONCOLOGY ICML Abstract(Abstract No: 367), 2019.
7. Jason R. Westin, MD , Loretta J. Nastoupil, MD MSc , Luis Fayad, MD , Fredrick B. Hagemeister, MD , Yasuhiro Oki, MD , Francesco Turturro, MD , Sairah Ahmed, MD , Maria Alma Rodriguez, MD , Hun Ju Lee , Raphael Eric Steiner, MD , Ranjit Nair, MBBS,MD , Simrit Parmar, MBBS , Ken H. Young , Timothy J. McDonnell, MD PhD , Hubert Chuang , Michael R Green, PhD , Sattva S Neelapu, MD , Eric Davis, MD. Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results. Blood(Blood (2019) 134 (Supplement_1): 1581), 2019.
8. Kartik Anand, Ethan Burns, Dahlia Sano, Sai Ravi Pingali, Jason Westin, Loretta J. Nastoupil, Hun Ju Lee, Felipe Samaniego, Simrit Parmar, Michael Wang, Misha Hawkins, Sherry Adkins, Luis Fayad, Raphael Steiner, Ranjit Nair, Sairah Ahmed, Nathan Hale Fowler, Sattva Swarup Neelapu, Swaminathan Padmanabhan Iyer;. Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. ASCO Abstract(Abstract No: 2540), 2019.
9. Ariela Noy, MD , Timothy S. Pardee, MD PhD , Liana Nikolaenko, MD , Raphael Eric Steiner, MD , Jeremy S. Abramson, MD MMSc , Kieron Dunleavy, MD , Sanjeev Luther, MBA. A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2and/or BCL6. Blood(Blood (2019) 134 (Supplement_1): 4087), 2019.
10. J.R. Westin, L. Nastoupil, F. Hagemeister, L. Fayad, K. Young, T. McDonnell, H. Chuang, S. Ahmed, R. Nair, R. Steiner, H. Lee, M. Rodriguez, S. Parmar, M. Green, S. Neelapu, R. Davis. SMART START: RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE PRIOR TO COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA. Hematological ONCOLOGY ICML Abstract(Abstract No: 042), 2019.
11. Chelsea C Pinnix, MD PhD , Jillian R Gunther, MD PhD , Bouthaina S. Dabaja, MD , Sherry Adkins, ANP , Misha Hawkins , Jason R. Westin, MD , Luis Fayad, MD , Sairah Ahmed, MD , Nathan H. Fowler, MD , Fredrick B. Hagemeister, MD , Swaminathan P. Iyer, MD , Maria Alma Rodriguez, MD , Hun Ju Lee , Raphael E Steiner, MD , Ranjit Nair, MBBS,MD , Paolo Strati, MD , Simrit Parmar, MBBS , Felipe Samaniego, MD , Michael Wang, MD , Sattva S Neelapu, MD , Loretta J. Nastoupil, MD MSc. Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma. Blood(Blood (2019) 134 (Supplement_1): 1609), 2019. e-Pub 2019.
12. Nathan H Fowler, MD , Loretta J. Nastoupil, MD MSc , Collin Chin, MBBS , Paolo Strati, MD , Fredrick B. Hagemeister, MD , Luis E. Fayad, MD , Jason R. Westin, MD , Sheryl G Forbes , Janine Arafat , Lei Feng, MS , Ranjit Nair, MBBS,MD , Raphael E Steiner, MD , Felipe Samaniego, MD , Sattva S Neelapu, MD. A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma. Blood(Blood (2019) 134 (Supplement_1): 348), 2019.
13. Jason R. Westin, MD , Nathan H. Fowler, MD , Loretta J. Nastoupil, MD MSc , Sattva S Neelapu, MD , Hun Ju Lee , Fredrick B. Hagemeister, MD , Maria Alma Rodriguez, MD , Raphael E Steiner, MD , Sairah Ahmed, MD , Simrit Parmar, MBBS , Ranjit Nair, MBBS,MD , Rebecca Harrison, MD , Luis Fayad, MD. A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma. Blood(Blood (2019) 134 (Supplement_1): 4086), 2019.
14. Dahlia Sano, MD , Paolo Strati, MD , Pedro Alcedo, MD , V Ahalya Rao, MD , Prachee Singh , Roberto N. Miranda, MD , Jillian R Gunther, MD PhD , Chelsea Camille Pinnix, MD PhD , Bouthaina S. Dabaja, MD , Feng Lei, MS , Hun Ju Lee, MD , Raphael E Steiner, MD. Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse. Blood(Blood (2019) 134 (Supplement_1): 5291), 2019.
15. Loretta J. Nastoupil, MD MSc , Jason R. Westin, MD , Fredrick B. Hagemeister, MD , Hun Ju Lee , Luis Fayad, MD , Felipe Samaniego, MD , Sairah Ahmed, MD , Linda Claret , Raphael E Steiner, MD , Ranjit Nair, MBBS,MD , Simrit Parmar, MBBS , Maria Alma Rodriguez, MD , Michael L. Wang, MD , Michael R Green, PhD , Eric Davis, MD , Sattva S Neelapu, MD , Nathan H Fowler, MD. Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL). Blood(Blood (2019) 134 (Supplement_1): 125), 2019.
16. Preetesh Jain, MBBS,MDDM,PhD , Hun Ju Lee, MD , Raphael Eric Steiner, MD , F. B. Hagemeister, MD , Felipe Samaniego, MD , Jason R. Westin, MD , Loretta J. Nastoupil, MD MSc , Sairah Ahmed, MD , Swaminathan P. Iyer, MD , Jorge Enrique Romaguera, MD , Shuangtao Zhao, PhD , Krystle Nomie, PhD , Chi Young Ok, MD , Rashmi Kanagal-Shamanna, MD , Onyeka Oriabure , Guofang Xu, MD , Liang Zhang, MD PhD , Changying Jiang, PhD , Dayoung Jung , Lucy Navsaria, MB BCh BAO , Wendy Chen , Omar Moghrabi , Tayyaba Nizam , Chloe Marie McClain , Maria Badillo , Selvi Thirumurthi , David Santos , Guilin Tang, MD , Keyur Patel, MD PhD , Sattva S Neelapu, MD , Linghua Wang, PhD , Nathan H. Fowler, MD , Michael L. Wang, MD. Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial. Blood(Blood (2019) 134 (Supplement_1): 3988), 2019.
17. Changying Jiang, PhD , Shaojun Zhang, PhD , Yuanxin Wang , Rongjia Zhang , Yang Liu, MD , Joseph Mitchell McIntosh , Guangchun Han, PhD , Ruiping Wang, PhD , David Santos , Maria Badillo , Angela Leeming , Zhihong Chen , Kimberly Hartig , John Bigcal , Hun Ju Lee , Raphael E Steiner, MD , Jorge Enrique Romaguera, MD , Preetesh Jain, MBBS, MDDM, PhD , Krystle Nomie, PhD , Andy Futreal, PhD , Linghua Wang, PhD , Michael L. Wang, MD. Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq. Blood(Blood (2019) 134 (Supplement_1): 5217), 2019.
18. Dahlia Sano, Loretta J. Nastoupil, Nathan H. Fowler, Luis Fayad, F. B. Hagemeister, Hun Ju Lee, Felipe Samaniego, Michael Wang, Maria Alma Rodriguez, Swaminathan P Iyer, Simrit Parmar, Raphael Steiner, Ranjit Nair, Sherry Adkins, Sara Arafat, Ahalya Rao, Liliana Vallejo, Misha Hawkins, Yiming Chen, Jason R. Westin, and Sattva S. Neelapu. Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell LymphomaClinically Relevant Abstract. ASH Annual Meeting 2018, 2018.
19. Chaudhry M, Steiner RE, Claussen CM, Patel K, Lee HC, Weber DM, Thomas SK, Feng C, Kramer M, Amini B, Orlowski RZ, Feng L, Manasanch EE. Carfilzomib-Based Combination Regimens Are Highly Effective Frontline Therapies for Multiple Myeloma and Waldenström's Macroglobulinemia. ASH Abstract 130(Suppl 1):1880. e-Pub 2017.
20. Steiner RE, Fanale MA. New Strategies for the Treatment of Early Stage Classical Hodgkin Lymphoma (cHL). Clinical Lymphoma, Myeloma & Leukemia 17:S153–S155. e-Pub 2017.

Book Chapters

1. Karp DD, Falchook G. Lymphoma. In: Handbook of Targeted Cancer Therapy and Immunotherapy. second. Wolters Kluwer, 2018.